Search company, investor...

Predict your next investment

Academic/University
qubis.co.uk

Investments

57

Funds

1

About QUBIS

QUBIS was established in 1984 by The Queen's University of Belfast to commercialize the University's research and development activities through the formation of spin-out businesses. The University, through QUBIS Ltd, takes an equity holding in a new spin-out venture in return for an investment of cash and/or Intellectual Property. Qubis' aim is to 'pull through' appropriate R & D from the laboratory into the commercial marketplace.

Headquarters Location

Queen’s University Belfast 63 University Road

Belfast, Northern Ireland, BT7 1NN,

United Kingdom

Want to inform investors similar to QUBIS about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest QUBIS News

Congratulations to portfolio company, Re-Vana Therapeutics, on securing a £10m investment

Jan 18, 2023

2328 18 Jan Posted at 10:54h in Uncategorised by admin One of Queen’s technology spin-out companies, Re-Vana Therapeutics, has attracted £10m of investment for research into sight-threatening eye disease. Article taken from: https://www.qub.ac.uk/News/ Pictured L-R are: Re-Vana Co-Founder, Professor Raj Thakur; QUBIS CEO, Brian McCaul; and Re-Vana Co-Founder and Queen’s University Pro-Vice-Chancellor, Professor David Jones. The company’s innovative method of sustained-release therapeutics can replace regular invasive treatment, increasing the quality of care for patients. The investment comes from a financing round led by  Visionary Ventures  with additional US investors ExSight Ventures, InFocus Capital Partners and existing UK investors TechStart Ventures, Co Fund NI and  Qubis Ltd . In conjunction with this financing,  Re-Vana’s  Board of Directors and Scientific Advisory Board have been further strengthened by the appointment of Robert Avery MD of Visionary Ventures to the Board of Directors and Michael O’Rourke as Board Chair. Speaking about the investment, Michael O’Rourke, President, Chief Executive Officer and Board Chair of Re-Vana Therapeutics said: “Financing from new and existing investors during this challenging time is a testament to the potential of Re-Vana’s technologies for sustained delivery of biologic therapeutics. “We are especially fortunate to have received financing from multiple, highly-respected, US ophthalmic-focused venture capital firms and UK investors. Their proven knowledge and expertise in ophthalmology are invaluable additions to Re-Vana as we accelerate the development of our biologic therapeutics pipeline and expand our strategic partnerships.” Re-Vana was cofounded by Professor Raj Thakur and Queen’s University Pro-Vice-Chancellor Professor David Jones. Welcoming the multi million pound investment, Professor Jones said: “This multi million pound investment reflects the expertise and innovation that Northern Ireland generates and we are delighted that Re-Vana can continue its ground breaking work in ophthalmology. “Queen’s University is a driver of innovation and talent and we are proud of our research and academic excellence as societal and economic drivers in Belfast, Northern Ireland and across the globe.” Professor Raj Thakur added: “There has been a longstanding challenge in maintaining the necessary drug levels to treat a range of ocular diseases without frequent administrations. Our novel concept of photocrosslinked drug delivery systems  means the need for intravitreal injections can be greatly reduced, decreasing the burden on patients and healthcare systems”. Re-Vana was established to focus on the development of internal therapeutics as well as external strategic collaborations with industry and, to date has raised more than $17.75M to support the development of sustained release biologics.” On behalf of Queen’s QUBIS has supported over 100 spin-out companies which raise millions of pounds of investment, creating thousands of jobs. QUBIS CEO Brian McCaul said: “We are proud to have helped form Re-Vana, becoming their first investor and continuing to show our support in each round. To see this company attract investment for so many US based specialist Ophthalmology funds is a testament to the innovative potential of Queen’s research and Northern Ireland innovation capability.”

QUBIS Investments

57 Investments

QUBIS has made 57 investments. Their latest investment was in Re-Vana as part of their Series A on November 11, 2022.

CBI Logo

QUBIS Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/30/2022

Series A

Re-Vana

$11.9M

No

8

11/2/2022

Unattributed VC

CV6 Therapeutics

$9.2M

Yes

2

9/21/2022

Seed

AMPLY Discovery

$1.01M

Yes

3

9/6/2022

Pre-Seed

Subscribe to see more

$99M

Subscribe to see more

10

8/8/2022

Seed - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/30/2022

11/2/2022

9/21/2022

9/6/2022

8/8/2022

Round

Series A

Unattributed VC

Seed

Pre-Seed

Seed - II

Company

Re-Vana

CV6 Therapeutics

AMPLY Discovery

Subscribe to see more

Subscribe to see more

Amount

$11.9M

$9.2M

$1.01M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

2

3

10

10

QUBIS Fund History

1 Fund History

QUBIS has 1 fund, including QUBIS Innovation Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

QUBIS Innovation Fund

$1.65M

1

Closing Date

Fund

QUBIS Innovation Fund

Fund Type

Status

Amount

$1.65M

Sources

1

QUBIS Team

3 Team Members

QUBIS has 3 team members, including current Chief Executive Officer, Frank Bryan.

Name

Work History

Title

Status

Frank Bryan

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Frank Bryan

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.